Immix Biopharma, Inc. IMMX Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immix Biopharma, Inc.'s total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immix Biopharma, Inc.'s total liabilities & equity?
- Immix Biopharma, Inc. (IMMX) reported total liabilities & equity of $95.82M in Q1 2026.
- How has Immix Biopharma, Inc.'s total liabilities & equity changed year-over-year?
- Immix Biopharma, Inc.'s total liabilities & equity increased by 381.7% year-over-year, from $19.89M to $95.82M.
- What is the long-term trend for Immix Biopharma, Inc.'s total liabilities & equity?
- Over 5 years (2020 to 2025), Immix Biopharma, Inc.'s total liabilities & equity has grown at a 186.9% compound annual growth rate (CAGR), from $539.6K to $104.84M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.